Skip to main content

Table 1 Comparisons between erenumab responders and non-responders in the 91 triptan users

From: Association between response to triptans and response to erenumab: real-life data

  Erenumab responders (n = 58) Erenumab non-responders (n = 33) P value
N, %
 Female 49 (84.5) 30 (90.9) 0.384
 Chronic Migraine 53 (91.4) 29 (87.9) 0.591
 Medication overuse 38 (65.5) 23 (69.7) 0.683
 Aura 21 (36.2) 10 (30.3) 0.568
 Allodynia 33 (56.9) 15 (45.5) 0.293
Preventive treatment failures    0.464
 2–4 36 (62.1) 23 (69.7)  
  > 4 22 (37.9) 10 (30.3)  
Triptan responders 51 (87.9) 22 (66.7) 0.014
Mean ± SD
 Age 46.6 ± 9.5 46.6 ± 10.9 0.926
 Migraine duration, years 25.0 ± 11.2 29.3 ± 12.3 0.143
 Monthly headache days 21.8 ± 7.9 18.3 ± 9.4 0.084
 Monthly migraine days 18.2 ± 7.1 17.8 ± 9.3 0.827
 Monthly medication days 18.2 ± 8.7 18.6 ± 8.2 0.833
 Mean headache intensity 7.8 ± 1.8 7.7 ± 1.7 0.792